Exagen Inc. (XGN) is an innovative company that is making significant contributions to the healthcare industry by revolutionizing patient care with cutting-edge testing procedures. It operates as a commercial-stage diagnostics company with a focus on autoimmune diseases. Founded in 2002 and based in Vista, California, the publicly-traded company develops, manufactures, and markets diagnostic tests under the AVISE® brand, aimed at providing more accurate, timely, and cost-effective diagnoses for complex autoimmune conditions.
Exagen’s flagship product is AVISE CTD, a proprietary diagnostic test that helps physicians diagnose and manage systemic lupus erythematosus (SLE) and other connective tissue diseases. Over the years, the company has expanded its product line to include tests for rheumatoid arthritis, vasculitis, and antiphospholipid syndrome, among other conditions.
The company stands out for its commitment to cutting-edge research and development, often in partnership with leading medical institutions. Exagen’s pioneering spirit and dedication to delivering quality care to patients with autoimmune diseases is evident in their extensive research collaborations, numerous patents, and a steady stream of innovative diagnostic tests.
Exagen’s contribution to the healthcare industry is not only limited to diagnostics. It has launched a proprietary disease activity metric, "Cell-bound complement activation products" (CB-CAPs), that like the AVISE tests, enables clinicians to effectively monitor disease activity in patients with systemic lupus erythematosus, helping guide treatment decisions and improve patient outcomes.
Exagen’s approach places the patient at the center of its innovation endeavors. Through the delivery of highly specific and sensitive diagnostic testing, they aim to personalize patient care and management, improve health outcomes, and eventually reduce costs for both patients and healthcare providers. Bridging the gap between medical research and patient care, Exagen continues to drive advancement in autoimmune disease diagnosis and monitoring, playing a vital role in the journey to improve individual patient care in a challenging and evolving therapeutic area.
A key strength lies in the company's solid reputation for accuracy and reliability. Alongside their robust product development pipeline and their partnerships with significant industry players, this positions them firmly at the forefront of the autoimmune diagnostic sector. As a result, Exagen Inc. has quickly become a leader in the diagnostic and healthcare market, cementing their status as a go-to solution for autoimmune disease diagnostics.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Jorey Chernett, a 10% owner of Exagen Inc. (XGN), purchased 71,315 shares for $373,000 at an average price of $5.23 per share on November 11, 2026, increasing his direct ownership to 2.70 million shares. This open-market purchase was reported via an SEC Form 4 filing, with the weighted average price derived from multiple transactions between $4.82 and $5.42. Chernett also indicated an intent to disgorge a short-swing profit related to these matchable transactions.
Exagen reported record third-quarter revenue of $18.4 million, achieving 11% year-to-date growth and over 30% adjusted EBITDA improvement. The company reaffirmed its full-year revenue guidance of $72 million to $75 million, driven by expanding product adoption, increased reimbursement, and planned innovations like a myositis offering in early 2027. Strategic initiatives also include expanding sales territories, leveraging AI for workflow optimization, and growing pharma services revenue, which nearly doubled year-to-date.
Exagen Inc. announced its financial results for the third quarter of 2026, reporting a 7% increase in total revenue to $18.4 million compared to the same period in 2025. Year-to-date revenue grew 11%, while the net loss was reduced by 12% and adjusted EBITDA loss improved by over 30%. The company also reiterated its full-year 2026 revenue guidance of $72 million to $75 million and plans to launch a myositis offering in early 2027.
Exagen Inc., Qventus, and Welldoc have been recognized with Gold honors in the 2026 Healthcare Innovation Impact Awards for their innovative solutions. Exagen's AVISE platform aids in diagnosing complex autoimmune conditions, Qventus uses AI to streamline perioperative workflows, and Welldoc provides personalized digital coaching for chronic cardiometabolic conditions. These solutions demonstrate diverse technological approaches to supporting clinicians, patients, and healthcare operations.
Exagen Inc. (Nasdaq: XGN), a provider of autoimmune testing, announced its management will participate in two upcoming investor conferences in November 2026. These include Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum, where they will present on innovative diagnostics for immunology applications, and Craig-Hallum's Alpha Select Conference. The company specializes in diagnostics for complex autoimmune conditions like lupus, rheumatoid arthritis, and Sjögren's disease.
Exagen Inc. (Nasdaq: XGN) announced its participation in two upcoming investor conferences: Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026, and Craig-Hallum's Alpha Select Conference on November 17, 2026. The company, a provider of innovative autoimmune testing, will meet with investors and present on innovative diagnostics for immunology applications.
Exagen Inc. announced its participation in two upcoming investor conferences: Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026, and Craig-Hallum's Alpha Select Conference on November 17, 2026. Management will meet with investors and participate in a panel discussion at the Canaccord Genuity forum. Exagen is a specialized diagnostics company focused on autoimmune conditions, known for its AVISE® CTD test.
Jorey Chernett, a 10% owner of Exagen Inc (XGN), recently purchased 14,000 shares, increasing his total holdings to 2,618,540 shares. This insider buy signals potential conviction in the company, despite Exagen Inc's stock being significantly overvalued according to the GuruFocus GF Value, and a trailing twelve-month period showing more insider selling than buying activity. Investors are advised to consider this transaction alongside other fundamental and valuation factors.